SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

GSK kündigt neue Phase-II-Daten zu Efimosfermin bei MASH an

Valid market news retained in the public archive without immediate LiveCast distribution.

Related stories